01 A New Breakthrough in Alzheimer’s Disease Intervention
With the intensification of population aging, Alzheimer’s disease (AD) has become a severe challenge in the global public health sector. This degenerative disorder of the central nervous system, characterized by progressive cognitive decline and neuronal damage, currently has no cure. Most existing therapies only alleviate symptoms without halting pathological progression.

Collagen cyclic dipeptide, a core product developed by Hainan Huayan in the field of brain health, has been tested in an AAALAC internationally certified zebrafish laboratory. The results confirm its potential to significantly improve AD-related pathological features at the experimental level, with supporting scientific literature providing a solid foundation for its mechanism of action.

01 Authoritative Endorsement—AAALAC-Certified Laboratory
AAALAC is a globally authoritative nonprofit organization, and its certification represents the highest international standards in ethical care and scientific rigor for animal experiments. The certification requires experimental institutions not only to strictly comply with animal protection regulations in various countries but also to implement standardized practices exceeding benchmarks in animal husbandry, experimental design, and result traceability. The tests related to collagen cyclic dipeptide were conducted in an AAALAC-certified laboratory, ensuring the reliability and credibility of the experimental data from the source.

Notably, the collagen cyclic dipeptide tested has successfully earned the “Verified by Zebrafish” quality certification. This designation is based on its core value, confirmed by the aforementioned authoritative laboratory tests: the ability to significantly improve AD-related pathological features. It serves as dual hard evidence of both ingredient quality and scientific research value.

02 Zebrafish: An Ideal Model for Alzheimer’s Disease
Zebrafish are widely used in neurodegenerative disease research. Their disease-related genes share up to 82% homology with humans, and their brain structure, neurotransmitter systems, and blood-brain barrier function are highly similar to those of humans. The zebrafish AD model induced by okadaic acid (OKA) accurately simulates core pathological features such as beta-amyloid (Aβ) deposition, tau protein hyperphosphorylation, and cognitive decline, making it a reliable tool for screening AD intervention substances. The tests on collagen cyclic dipeptide were based on this well-established model, and the experimental results offer reference value for translation to human applications.

02 Scientific Evidence: Three Core Mechanisms of Cyclic Dipeptide in AD Pathology
Existing scientific literature has established a consensus: the pathological progression of AD involves multiple mechanisms, including Aβ deposition, tau protein abnormalities, neuroinflammation, and oxidative stress, making single-target interventions of limited effectiveness. Cyclic dipeptide, through a multi-dimensional mode of action—”reducing toxic deposits + protecting neural stem cells + penetrating the blood-brain barrier”—achieves comprehensive intervention in AD pathological processes.

Zebrafish In Vivo Experiments: Significant Intervention in AD-Related Pathology and Cognitive Impairment
In controlled experiments conducted in the AAALAC-certified laboratory, AD model zebrafish treated with cyclic dipeptide showed clear pathological improvements:

❖ Reduction of Toxic Deposits: The number of beta-amyloid plaques significantly decreased, and tau protein hyperphosphorylation was effectively inhibited. Abnormal accumulation of these substances is the most typical pathological hallmark of AD.
❖ Improvement in Cognitive Function: Through avoidance experiments and T-maze tests, cyclic dipeptide-treated zebrafish demonstrated significantly enhanced learning and memory abilities, successfully reversing cognitive decline induced by the AD model.
❖ Protection of Neuronal Integrity: Experiments confirmed that cyclic dipeptide reduces neuronal apoptosis and loss in zebrafish brains, maintaining the structural stability of neural networks.

Cellular Level: Regulating the MDM2-p53 Pathway to Protect Neural Stem Cells
Oxidative damage to human neural stem cells is a significant cause of neuronal loss in AD progression. Scientific literature indicates that cyclic dipeptide significantly mitigates hydrogen peroxide-induced damage in human neural stem cells. The core mechanism involves regulating the MDM2-p53 pathway:

❖ MDM2, a key regulator of the p53 protein, normally inhibits p53 activity via ubiquitination. However, oxidative stress in the AD pathological environment disrupts this pathway, leading to excessive p53-mediated apoptosis.
❖ Cyclic dipeptide specifically modulates the interaction between MDM2 and p53, suppressing abnormally activated apoptotic pathways, reducing neural stem cell damage, and providing a foundation for neuronal repair and regeneration.

Blood-Brain Barrier Penetration: Advantages of the Cyclic Structure
The blood-brain barrier is a major obstacle in AD drug development, as most large-molecule substances struggle to penetrate and reach the brain parenchyma to exert effects. The cyclic molecular structure of cyclic dipeptide exhibits unique advantages:

❖ Comparative studies in scientific literature show that cyclic peptides have higher blood-brain barrier penetration efficiency than linear peptides. Their rigid structure facilitates transport across cells or via endocytosis into the brain parenchyma.
❖ This property ensures that cyclic dipeptide can break through physiological barriers, directly act on brain lesion sites, and deliver targeted intervention effects, addressing the core challenge of traditional intervention substances being “difficult to enter the brain.”

03 Literature Consensus: Cyclic Dipeptide Offers a New Direction for AD Intervention

01 Scientific Value of Cyclic Dipeptide
The comprehensive intervention mechanism of cyclic dipeptide in AD pathological processes aligns with the current research shift from “symptomatic relief” to “addressing the root cause” in AD-related studies. Moreover, through triple validation—AAALAC-certified zebrafish experiments, the “Verified by Zebrafish” certification, and cellular molecular mechanism research—it demonstrates solid scientific value.

02 A Core Achievement by Hainan Huayan
Collagen cyclic dipeptide, as a core achievement by Hainan Huayan in the brain health sector, not only establishes a strong foundation for its quality through stringent standards but also marks a meaningful contribution to the product landscape in brain health. These scientific breakthroughs in cyclic dipeptide also provide new directions for ingredient innovation and application in the brain health field.

As research into the mechanism of cyclic dipeptide deepens and more preclinical studies advance, this naturally derived active substance holds promise for inspiring new developments in global AD-related research. In the future, rigorously researched innovative ingredients may continue to drive progress in neurodegenerative disease studies and the broader brain health field.